The longitudinal data on pediatric cancer survivors reveals a stark reality: kids "cured" in their first decade are presenting with the cardiovascular profiles and frailty of sixty-year-olds by the time they hit thirty. We celebrate a clean biopsy as a triumph, but we're ignoring the Iatrogenic Aging Debt accruing in the background.

Our current oncological paradigm is effectively a metabolic scorched-earth policy. When we use DNA-damaging agents and high-dose radiation to wipe out a malignant cluster, we're triggering a Systemic Senescence Event (SSE). We’re forcing the entire organism to hit its replicative limit early just to stop a single localized rebellion.

Think of the body's ecological niche. If cancer is an invasive species, our treatment is a forest fire. The forest is technically "saved," but the soil is sterilized, the canopy is gone, and the biome’s regenerative capacity is broken. We're creating a demographic of biological ghosts—people who are clinically cancer-free but whose cellular hardware has aged fifteen years in a six-month window. They're effectively excluded from future longevity benefits because their "repair floor" has been decimated.

We're curing cancer in the wrong sequence. We focus on the tumor’s death while ignoring the senescent legacy left in the surrounding tissue. It's a massive blind spot in our funding priorities. We need to move toward geroprotective oncology—a field where preserving the patient’s biological age is a primary endpoint, not a secondary casualty.

A ten-year survival gain isn't a victory if it costs twenty years of biological potential. We need to bridge the gap between oncology and senolytics. We shouldn't be administering a single dose of cisplatin without a concurrent strategy to mitigate the epigenetic erasure it causes. If we don't solve this, we aren't extending life; we’re just lengthening the duration of the decline.